Date Title
May 21, 2018
Realm Therapeutics - Data Presentation at IID 2018
RNS Number : 6495O Realm Therapeutics PLC 21 May 2018     Realm Therapeutics Presents Data Highlighting its Proprietary Immunomodulatory Technology's Potential in Acne and Psoriasis at IID 2018     MALVERN, PA , May 21, 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical
May 2, 2018
Realm Therapeutics - Annual Financial Report Available
RNS Number : 9097M Realm Therapeutics PLC 02 May 2018   Realm Therapeutics plc ("Realm Therapeutics" or the "Company")   Annual Report and Accounts Available   2 May 2018 -   Realm Therapeutics plc  (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics for
May 2, 2018
Realm Therapeutics - Final Results
RNS Number : 8258M Realm Therapeutics PLC 02 May 2018   THIS ANNOUNCEMENT IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE
May 2, 2018
Realm Therapeutics - Realm Files Registration for Nasdaq Listing of ADS
RNS Number : 8259M Realm Therapeutics PLC 02 May 2018   THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION
April 26, 2018
Realm Therapeutics - Notice of Results
RNS Number : 2760M Realm Therapeutics PLC 26 April 2018   Realm Therapeutics plc ("Realm Therapeutics", "Realm", or the "Company")   Notice of Full Year 2017 Results     April 26, 2018 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel
March 12, 2018
Realm Therapeutics - Second Price Monitoring Extn
RNS Number : 4711H Realm Therapeutics PLC 12 March 2018   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
March 12, 2018
Realm Therapeutics - Price Monitoring Extension
RNS Number : 4704H Realm Therapeutics PLC 12 March 2018   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
March 12, 2018
Realm Therapeutics - Clinical Update including PR013 Phase II results
RNS Number : 3372H Realm Therapeutics PLC 12 March 2018   THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014   Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic Conjunctivitis   MALVERN, PA ,
March 8, 2018
Realm Therapeutics - Presenting at Cowen Healthcare Conference
RNS Number : 0452H Realm Therapeutics PLC 08 March 2018   Realm Therapeutics to Present at the Cowen and Company 38 th Annual Health Care Conference   MALVERN, PA , March 8 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics
February 27, 2018
Realm Therapeutics - Patent portfolio strengthened with USPTO allowance
RNS Number : 9683F Realm Therapeutics PLC 27 February 2018   Realm Therapeutics Strengthens its Patent Portfolio with Two New USPTO Notice of Allowances   MALVERN, PA , February 27, 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel
Displaying 11 - 20 of 24

Search Investor Relations